Effect of growth hormone and oxandrolone treatment on glucose metabolism in Turner syndrome: A longitudinal study

Hormone Research

Volumn 53, Issue 1, 2000, Pages 1-8

  Joss, E E ^a,c   Zurbrugg R P ^b   Tonz O ^c   Mullis, P E ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b Wildermeth of Biel   (Switzerland)

^c NONE

Author keywords

Glucose metabolism; Growth hormone; Oxandrolone; Turner syndrome

Indexed keywords

FRUCTOSAMINE; GLUCOSE; HUMAN GROWTH HORMONE; INSULIN; OXANDROLONE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULINEMIA; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SCHOOL CHILD; TURNER SYNDROME;

ADOLESCENT; ADULT; ANABOLIC STEROIDS; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN; HUMAN GROWTH HORMONE; INSULIN; OXANDROLONE; SAFETY; SUPPORT, NON-U.S. GOV'T; TURNER SYNDROME;

EID: 0343443038     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Rosenfeld RG, Attie KM, Frane J, Brasel JA, Burstein S, Cara JF, Chernausek S, Gotlin RW, Kuntze J, Lippe BM, Mahoney CP, Moore WV, Saenger P, Johanson AJ: Growth hormone therapy of Turner's syndrome: Beneficial effect on adult height. J Pediatr 1998;132:319-324.
2. Menzinger G, Fallucca F, Andreani D: Gonadal dysgenesis and diabetes. Lancet 1966;i: 1269.
3. Nielsen J, Johansen K, Yde H: The frequency of diabetes mellitus in patients with Turner's syndrome and pure gonadal dysgenesis. Acta Endocrinol (Copenh) 1969;62:251-269.
4. Karp M, Snir A, Doron M, Mammon Z, Laron Z: Glucose tolerance test and insulin response in juvenile patients with gonadal dysgenesis. Mod Probl Paediatr 1975;12:251-259.
5. Rasio E, Antaki A, Van Campenhout J: Diabetes mellitus in gonadal dysgenesis: Studies of insulin and growth hormone secretion. Eur J Clin Invest 1976;6:59-66.
6. Van Campenhout J, Rasio E: Carbohydrate tolerance in gonadal dysgenesis. Am J Obstet Gynecol 1979;135:863-875.
7. Polychronakos C, Letarte J, Collu R, Ducharme JR: Carbohydrate intolerance in children and adolescents with Turner syndrome. J Pediatr 1980;96:1009-1014.
8. Costin G, Kogut MD: Carbohydrate intolerance in gonadal dysgenesis: Evidence for insulin resistance and hyperglucagonemia. Horm Res 1985;22:260-269.
9. Wilson DM, Frane JW, Sherman B, Johanson AJ, Hintz R, Rosenfeld RG. and the Genentech Turner's Collaborative Group: Carbohydrate and lipid metabolism in Turner syndrome: Effect of therapy with growth hormone, oxandrolone, and a combination of both. J Pediatr 1988;112:210-217.
10. Heinze E, Schlickenrieder J, Holl RW, Ebert E: Reduced secretion of GIP (gastric inhibitory polypeptide) in Turner patients with impaired glucose tolerance. Eur J Pediatr 1991;150:339-342.
11. Holl RW, Heinze E: Gestörte Glukosetoleranz und Diabetes mellitus bei Ullrich-Turner-Syndroni. Monatsschr Kinderheilkd 1991;39:676-680.
12. Weise M. James D, Leitner CH, Hartmann KKP, Böhles HJ, Attanasio A, and the German Lilly UTS Study Group: Glucose metabolism in Ullrich-Turner syndrome: Long-term effects of therapy with human growth hormone. Horm Res 1993;39:36-41.
13. Forbes AP, Engel E: The high incidence of diabetes mellitus in 41 patients with gonadal dysgenesis and their close relatives. Metabolism 1963;12:420-443.
14. Stoppoloni G, Frisco F, Alfano C, Iafusco D, Marrazzo G, Paolisso G: Characteristics of insulin resistance in Turner syndrome. Diabete Metab 1990;16:267-271.
15. Caprio S, Boulware M, Diamond M, Sherwin R, Carpenter TO, Rubin K, Amiel S, Press M, Tamborlane WV: Insulin resistance: An early metabolic defect of Turner's syndrome. J Clin Endocrinol Metab 1991;72:832-836.
16. Bratusch-Marrain PR, Smith D, DeFronzo RA: The effect of growth hormone on glucose metabolism and insulin secretion in man. J Clin Endocrinol Metab 1982;55:973-982.
17. Rosenfeld RG, Wilson DM, Dollar LA, Bennett A, Hintz RL: Both human pituitary growth hormone and recombinant DNA-derived human growth hormone cause insulin resistance at a postreceptor site. J Clin Endocrinol Metab 1982;54:1033-1038.
18. Landon J, Wynn V, Cooke JNC: Effect of anabolic steroid methandienone on carbohydrate metabolism in man. Metabolism 1962;11:501-507.
19. Godsland IF, Shennan NM, Wynn V: Insulin action and dynamics modelled in patients taking the anabolic steroid methandienone (Dianabol). Clin Sci (Colch) 1986;71:665-673.
20. Van Vliet G, Styne DM, Kaplan SL, Grumbach MM: Turner's syndrome and human growth hormone, biochemical studies: in Raiti S, Tolman RA (eds): Human Growth Hormone. New York, Plenum, 1986, pp 115-121.
21. Takano K, Shizume K, Hibi I, and the Members of the Committee for the Treatment of Turner's Syndrome: Turner's syndrome: Treatment of 203 patients with recombinant human growth hormone for one year. A multicentre study. Acta Endocrinol (Copenh) 1989;120: 559-568.
22. Häusler G, Frisch H: Growth hormone treatment in Turner's syndrome: Short-and long-term effects on metabolic parameters. Clin Endocrinol (Oxf) 1992;36:247-253.
23. Caprio S, Boulware SD, Press M, Sherwin RS, Rubin K, Carpenter TO, Plewe G, Tamborlane WV: Effect of growth hormone treatment on hyperinsulinemia associated with Turner syndrome. J Pediatr 1992;120:238-243.
24. van Teunenbroek A, de Muinck Keizer-Schrama SMPF, Aanstoot HJ, Stijnen T, Hoogerbrugge N, Drop SLS, and the Dutch Working Group on Growth Hormone: Carbohydrate and lipid metabolism during various growth hormone dosing regimens in girls with Turner syndrome. Metabolism 1999;48:7-14.
25. Stahnke N, Stubbe P, Keller E: Recombinant human growth hormone and oxandrolone in treatment of short stature in girls with Turner syndrome. Horm Res 1992;37(suppl 2):37-46.
26. Wass JAH, Cudworth AG, Bottazzo GF, Woodrow LC, Besser GM: An assessment of glucose intolerance in acromegaly and its response to medical treatment. Clin Endocrinol (Oxf) 1980;12:53-59.
27. Saenger P, Wesoly S, Wasserman EJ, Glickstein J, Issenberg H: Safety aspects of GH therapy in Turner syndrome (TS): No evidence for ventricular hypertrophy (VH) and normalisation of insulin levels after discontinuation of GH, Pediatr Res 1996;39:98A.
28. Clinical Practice Recommendations 2000: The Expert Committee on the Diagnosis and Classification of Diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2000;23:(suppl 1):S2-S19.
29. Frey BM: Glukosestoffwechsel bei Mädchen mit Turner Syndrom unter wachstumsfördernder Hormontherapie; Inaugural-Dissertation. Universität Bern, 1996.
30. Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV: Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med 1986;315:215-219.
31. Matthews DR, Hosker JP, Rudenski AS, Naylor BA. Treacher DF, Turner RC: Homeostasis model assessment: Insulin resistance and betacell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
32. Lillioja S, Mott DM, Howard BV, Bennett PH, Yki-Järvinen H, Freymond D, Nyomba BL, Zurlo F, Swinburn B, Bogardus C: Impaired glucose tolerance as a disorder of insulin action: Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 1988;318: 1217-1225.
33. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH: Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. Lancet 1989;i:1356-1359.
34. Köberling J: Zur Wertigkeit des oralen Glukosctoleranztestes. Internist (Berlin) 1980;21: 213-219.
35. Yudkin JS, Alberti KGMM, McLarty DG, Swai ABM: Impaired glucose tolerance: Is it a risk factor for diabetes or a diagnostic ragbag? Br Med J 1990;301:397-402.
36. Keen H, Jarrett RJ, McCartney P: The ten-year follow-up of the Bedford Survey (1962-1972): Glucose tolerance and diabetes. Diabetologia 1982;22:73-78.